ArticleIn vivo (Athens, Greece)
Dissociated FoxP3 Up-regulation With Functional Surface Marker Loss Defines a Convergent Treg Paradox Across Immunological Archetypes of IgA Nephropathy and IgA Vasculitis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimImmunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV) exhibit remarkable clinical heterogeneity, yet its underlying immunological diversity remains poorly characterized. We investigated whether high-dimensional peripheral blood immunophenotyping could identify distinct immunological archetypes and shared regulatory T cell (Treg) dysregulation across the clinical spectrum of IgAN and IgAV. PATIENTS AND
methodsFour patients with biopsy-proven IgAN or clinically confirmed IgAV were prospectively enrolled. Serial multicolor flow cytometry characterized T-cell subsets, Treg populations, and B-cell subpopulations relative to healthy controls.
resultsIndividual-level profiling revealed four distinct immunological archetypes: activated T-cell, B-cell dominant, severe dysregulator, and quiescent each correlating with a specific clinical trajectory from decade-long stability to fatal outcome. Cross-case analysis revealed a convergent Treg paradox across all archetypes, characterized by increased intracellular forkhead box protein P3 (FoxP3) expression concurrent with depletion of key functional surface markers, including cluster of differentiation 25 (CD25), L-selectin (CD62L), and cluster of differentiation 127 (CD127). This paradox was consistently observed across all four archetypes regardless of disease severity or treatment status.
conclusionIgAN and IgAV are not uniform immunological entities. The Treg Paradox, a dissociation between regulatory commitment and functional capacity may represent a shared pathogenic feature across clinically diverse phenotypes, warranting further validation as a potential basis for immunotype-guided precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.